144 related articles for article (PubMed ID: 35984168)
1. Efficacy and safety of pembrolizumab monotherapy in EGFR-mutant squamous cell lung cancer with PD-L1 over-expression: A case report.
Liu QX; Wei JG; Chen YY; Wang JF
Medicine (Baltimore); 2022 Aug; 101(33):e30099. PubMed ID: 35984168
[TBL] [Abstract][Full Text] [Related]
2. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
[TBL] [Abstract][Full Text] [Related]
3. First-line immune checkpoint therapy in metastatic squamous cell lung cancer harboring both EGFR mutation and high expression of PD-L1: A case report.
Hamai K; Tanahashi H; Ueno S; Konishi H; Matsumura M; Nomura A; Nakamoto K; Isoyama S; Tanimoto T; Shoda H; Ishikawa N
Thorac Cancer; 2020 Jun; 11(6):1716-1719. PubMed ID: 32291904
[TBL] [Abstract][Full Text] [Related]
4. [A Real-world Study on the Expression Characteristics of PD-L1 in Patients
with Advanced EGFR Positive NSCLC and Its Relationship with the
Therapeutic Efficacy of EGFR-TKIs].
Chen R; Gao X; Xu F; Zhang S; Ma L; Hu B
Zhongguo Fei Ai Za Zhi; 2023 Mar; 26(3):217-227. PubMed ID: 37035884
[TBL] [Abstract][Full Text] [Related]
5. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
Hsu PC; Jablons DM; Yang CT; You L
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer.
Miyawaki E; Murakami H; Mori K; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Wakuda K; Ono A; Kenmotsu H; Naito T; Takahashi T
Jpn J Clin Oncol; 2020 May; 50(5):617-622. PubMed ID: 32211792
[TBL] [Abstract][Full Text] [Related]
7. A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.
Lisberg A; Cummings A; Goldman JW; Bornazyan K; Reese N; Wang T; Coluzzi P; Ledezma B; Mendenhall M; Hunt J; Wolf B; Jones B; Madrigal J; Horton J; Spiegel M; Carroll J; Gukasyan J; Williams T; Sauer L; Wells C; Hardy A; Linares P; Lim C; Ma L; Adame C; Garon EB
J Thorac Oncol; 2018 Aug; 13(8):1138-1145. PubMed ID: 29874546
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y
J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363
[TBL] [Abstract][Full Text] [Related]
9. Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments.
Omori S; Kenmotsu H; Abe M; Watanabe R; Sugino T; Kobayashi H; Nakashima K; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Ohde Y; Endo M; Akiyama Y; Nakajima T; Takahashi T
Int J Clin Oncol; 2018 Dec; 23(6):1052-1059. PubMed ID: 29948239
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Mok TSK; Wu YL; Kudaba I; Kowalski DM; Cho BC; Turna HZ; Castro G; Srimuninnimit V; Laktionov KK; Bondarenko I; Kubota K; Lubiniecki GM; Zhang J; Kush D; Lopes G;
Lancet; 2019 May; 393(10183):1819-1830. PubMed ID: 30955977
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
[TBL] [Abstract][Full Text] [Related]
12. [A Real-world Study on the Assessment of Pathological Characteristics and Targeted Therapeutic Effect of Non-small Cell Lung Cancer Patients with Positive Driving Genes and High PD-L1 Expression].
Zhang H; Yang X; Li K; Wang J; Lv J; Li X; Zhang X; Qin N; Zhang Q; Wu Y; Ma L; Gai F; Hu Y; Zhang S
Zhongguo Fei Ai Za Zhi; 2021 Feb; 24(2):78-87. PubMed ID: 33478196
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G
Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994
[TBL] [Abstract][Full Text] [Related]
14. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
Toki MI; Mani N; Smithy JW; Liu Y; Altan M; Wasserman B; Tuktamyshov R; Schalper K; Syrigos KN; Rimm DL
J Thorac Oncol; 2018 Dec; 13(12):1884-1896. PubMed ID: 30267840
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
16. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
17. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
[TBL] [Abstract][Full Text] [Related]
18. Concurrent High PD-L1 Expression and CD8
Shimoda Y; Shibaki R; Yoshida T; Murakami S; Shirasawa M; Torasawa M; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Ohe Y; Motoi N
Clin Lung Cancer; 2022 Sep; 23(6):477-486. PubMed ID: 35644780
[TBL] [Abstract][Full Text] [Related]
19. Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors.
Lau SCM; Fares AF; Le LW; Mackay KM; Soberano S; Chan SW; Smith E; Ryan M; Tsao MS; Bradbury PA; Pal P; Shepherd FA; Liu G; Leighl NB; Sacher AG
Clin Lung Cancer; 2021 Jul; 22(4):253-259. PubMed ID: 33582070
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer.
Besse B; Garrido P; Cortot AB; Johnson M; Murakami H; Gazzah A; Gil M; Bennouna J
Lung Cancer; 2020 Apr; 142():63-69. PubMed ID: 32114283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
